THRA
Thyroid hormone receptor alpha
As of the edition of 20 October 2026, THRA (thyroid hormone receptor alpha, UniProt P10827) has 4 drugs tested at it and 16 companies on the list, 0 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P10827
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 10
- Disease areas
- Hormones; Cancer; Heart and blood vessels; Nutrition and metabolism; Nervous system; Inherited and neonatal; Mental health; Urinary and reproductive
- Registered trials of its drugs
- 151
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Levothyroxine | Marketed | Phase 4 | none listed |
| Liothyronine | Marketed | Phase 4 | none listed |
| Tiratricol | Marketed | Phase 3 | none listed |
| Dextrothyroxine | Marketed | Phase 3 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 3 |
| Engaged | 11 |
| Undetermined | 2 |
| Total on the list | 16 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| IBSA Institut Biochimique | Route B |
| ASKA Pharmaceutical | Route B |
The other 13 companies at THRA
In the product16 companies in all; 13 are not named here, and no score is.
See the 16 companies at THRA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.